Kymera Therapeutics announced that it expects to initiate a Phase 1 clinical trial in the second half of 2024 and report the Phase 1 results in 2025.TYK2 degrader program (KT-294)TYK2 is a member of the Janus Kinase family required for Type I interferon (IFN), interleukin-12 (IL-12") and interleukin-23 ("IL-23") signaling with both genetic and clinical validation in autoimmune and inflammatory diseases. The Company intends to initiate a Phase 1 clinical trials in the first half of 2025 and report the Phase 1 results In 2025. IRAK4 degrader program (KT-474/SAR444656).

KT-474 is a first-in-class IRAK4 degrader in Phase 2 clinical trials for the treatment of hidradenitis suppurativa ("HS") and atopic dermatitis ("AD"). Any forward-looking statements in this Item 8.01 are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: the timing and anticipated results of current preclinical studies and clinical trials, supply chain, strategy and future operations; the delay of any current and future preclinical studies or clinical trials or the development of Kymera Therapeutics' drug candidates, including those for KT-621, KT-294 and KT-474; the risk that the results or interim results of current preclinical studies & clinical trials may not be predictive of future results in connection with current or future preclinical and clinical trials; and Kymera's financial condition and expected cash runway into the first half of 2026.